Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Aug 22;24(1):1041.
doi: 10.1186/s12885-024-12814-5.

A dosimetric comparison of brachytherapy sources for endometrial cancer: an electronic brachytherapy and an iridium-192 source with multichannel cylinders and a three-dimensional technique

Affiliations
Comparative Study

A dosimetric comparison of brachytherapy sources for endometrial cancer: an electronic brachytherapy and an iridium-192 source with multichannel cylinders and a three-dimensional technique

Wenhui Wang et al. BMC Cancer. .

Abstract

Background and purpose: Ir192 vaginal brachytherapy (IBT) is commonly used for patients with postoperative endometrial cancer (EC). We devised a novel multichannel vaginal applicator that could be equipped with an electronic brachytherapy (EBT) device. We aimed to explore the differences in physical parameters between the EBT and IBT.

Materials and methods: This retrospective study included 20 EC patients who received adjuvant IBT from March 1, 2023, to May 1, 2023. Multichannel vaginal cylinders were used, and three-dimensional plans were generated. We designed an electronic multichannel vaginal applicator model and simulated a three-dimensional EBT plan. In order to ensure comparability, D90 of the CTV for the EBT plan was normalized to be equivalent to that of the IBT plan for the same patient.

Results: Twenty EBT plans were compared with 20 IBT plans. Results showed, the mean D90 value of clinical target volume (CTV) was 536.1 cGy for both treatment plans. For the mean dose of CTV, the EBT was significantly greater (738.3 vs. 684.3 cGy, p = 0.000). There was no significant difference in CTV coverage between the EBT and IBT plans. For high-dose areas (V200% and V150%), the EBTs were significantly greater. There were no significant differences in the maximum doses to the vaginal mucosa between the EBT and IBT, whether at the apex or in the middle segment. For the bladder and rectum, both the low-dose area and high-dose area were significantly lower in the EBT plans. For the conformity index, there was no significant difference between the EBT and IBT plans. For the dose homogeneity index, the EBT value was lower.

Conclusion: In conclusion, under the premise of a three-dimensional brachytherapy plan, for patients receiving multichannel vaginal applicator brachytherapy, compared with IBT, EBT could reduce the dose to the surrounding organs at risk while maintaining the dose in the target area.

Keywords: Electronic brachytherapy; Iridium-192 brachytherapy; Multichannel vaginal applicator; Physical parameters.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
(a) Multichannel instrument equipped with an Ir192 vaginal brachytherapy device; (b) Multichannel (2-3-2 layout) model equipped with an electronic brachytherapy device
Fig. 2
Fig. 2
The dose-volume histogram (DVH) for the Ir192 brachytherapy and electronic brachytherapy plans from one patient. The horizontal axis represented absolute dose, and the vertical axis represented relative volume ………… CTV in IBT, ________ CTV in EBT; ………… Small Intestine in IBT, ________ Small Intestine in EBT;………… Sigmoid colon in IBT, ________ Sigmoid colon in EBT; ………… Bladder in IBT, ________ Bladder in EBT; ………… Rectum in IBT, ________ Rectum in EBT;
Fig. 3
Fig. 3
The dose distribution map for Ir192 brachytherapy and electronic brachytherapy plan for one patient. The three images on the left show Ir192 brachytherapy plan, and the three images on the right show electronic brachytherapy plan

Similar articles

References

    1. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2021;31(1):12–39.10.1136/ijgc-2020-002230 - DOI - PubMed
    1. Dickler A, Kirk MC, Coon A, Bernard D, Zusag T, Rotmensch J, et al. A dosimetric comparison of Xoft Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer. Brachytherapy. 2008;7(4):351–4. 10.1016/j.brachy.2008.05.003 - DOI - PubMed
    1. Mobit PN, Nguyen A, Packianathan S, He R, Yang CC. Dosimetric comparison of brachytherapy sources for high-dose-rate treatment of endometrial cancer: (192)ir, (60)Co and an electronic brachytherapy source. Br J Radiol. 2016;89(1059):20150449. 10.1259/bjr.20150449 - DOI - PMC - PubMed
    1. Dickler A, Puthawala MY, Thropay JP, Bhatnagar A, Schreiber G. Prospective multicenter trial utilizing electronic brachytherapy for the treatment of endometrial cancer. Radiation Oncol (London England). 2010;5:67.10.1186/1748-717X-5-67 - DOI - PMC - PubMed
    1. Dooley WC, Thropay JP, Schreiber GJ, Puthawala MY, Lane SC, Wurzer JC, et al. Use of electronic brachytherapy to deliver postsurgical adjuvant radiation therapy for endometrial cancer: a retrospective multicenter study. OncoTargets Therapy. 2010;3:197–203. 10.2147/OTT.S13593 - DOI - PMC - PubMed

Publication types

LinkOut - more resources